Anzeige
Erschienen in:
05.08.2019 | Nephrology - Original Paper
Outcomes of sirolimus regimens in 65-year-old and older kidney transplant recipients: a registry-based observational study
Erschienen in: International Urology and Nephrology | Ausgabe 11/2019
Einloggen, um Zugang zu erhaltenAbstract
Purpose
In large observational studies of adult kidney transplant recipients (KTRs) where older adults (65 years old and older) were not well represented, the mammalian target of rapamycin inhibitors (mTOR inhibitors) has poorer outcomes than the standard tacrolimus–mycophenolate–steroids (TAC–MPA–S) regimen. We conducted this study to compare the outcomes of regimens containing the common mTOR inhibitor, sirolimus (SRL) against TAC–MPA–S in older adult KTRs.
Methods
Using the 2000–2016 Scientific Registry of Transplant Recipients, Cox multivariable regression models were conducted to analyze the patient and graft outcomes associated with regimens containing SRL, steroids (S) and cyclosporine (CSA), tacrolimus (TAC), or mycophenolate (MPA) vs. the standard (TAC–MPA–S) regimen in older adult KTRs.
Results
Included in the analysis were 15,008 (95.19%) older adult KTRs on standard (TAC–MPA–S) regimen, 242 (1.53%) on SRL–MPA–S, 300 (1.90%) on SRL–TAC–S, and 217 (1.38%) on SRL–CSA–S. Compared with the standard regimen, the adjusted risks of all-cause death and overall graft loss over a maximum 5-year follow-up were highest with SRL–MPA–S, intermediate with SRL–TAC–S and not significantly different with SRL–CSA–S. The adjusted risks of all-cause death and overall graft loss were modified by a pre-transplant history of malignancy in older adult KTRs on SRL–TAC–S, not in those on SRL–MPA–S or SRL–CSA–S.
Conclusions
In older adult kidney transplant recipients, SRL–TAC–S or SRL–MPA–S, but not SRL–CSA–S is associated with higher risks of death and allograft loss than standard TAC–MPA–S regimen and a pre-transplant malignancy history worsens these risks in patients on SRL–TAC–S. Confirmation of our findings by a prospective randomized trial is needed before translation into clinical practice can be recommended.